Literature DB >> 22956820

Long-term outcomes of IgA nephropathy presenting with minimal or no proteinuria.

Eduardo Gutiérrez1, Isabel Zamora, José Antonio Ballarín, Yolanda Arce, Sara Jiménez, Carlos Quereda, Teresa Olea, Jorge Martínez-Ara, Alfons Segarra, Carmen Bernis, Asunción García, Marian Goicoechea, Soledad García de Vinuesa, Jorge Rojas-Rivera, Manuel Praga.   

Abstract

The long-term outcome of patients with IgA nephropathy who present with normal renal function, microscopic hematuria, and minimal or no proteinuria is not well described. Here, we studied 141 Caucasian patients with biopsy-proven IgA nephropathy who had minor abnormalities at presentation and a median follow-up of 108 months. None of the patients received corticosteroids or immunosuppressants. We reviewed renal biopsies using the Oxford classification criteria. In this sample, 46 (32%) patients had mesangial proliferation, whereas endocapillary proliferation, focal glomerulosclerosis, and tubulointerstitial abnormalities were uncommon. Serum creatinine increases >50% and >100% were observed in five (3.5%) patients and one (0.7%) patient, respectively; no patients developed ESRD. After 10, 15, and 20 years, 96.7%, 91.9%, and 91.9% of patients maintained serum creatinine values less than a 50% increase, respectively. Using Cox proportional hazards regression, the presence of segmental glomerulosclerosis was the only factor that significantly associated with a >50% increase in serum creatinine. Clinical remission occurred in 53 (37.5%) patients after a median of 48 months. Proteinuria>0.5 and >1.0 g/24 h developed in 21 (14.9%) and 6 (4.2%) patients, respectively. Median proteinuria at the end of follow-up was 0.1 g/24 h, with 41 (29.1%) patients having no proteinuria. At presentation, 23 (16.3%) patients were hypertensive compared with 30 (21.3%) patients at the end of follow-up; 59 (41.8%) patients were treated with renin-angiotensin blockers because of hypertension or increasing proteinuria. In summary, the long-term prognosis for Caucasian patients with IgA nephropathy who present with minor urinary abnormalities and normal renal function is excellent.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22956820      PMCID: PMC3458461          DOI: 10.1681/ASN.2012010063

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  29 in total

1.  HLA has strongest association with IgA nephropathy in genome-wide analysis.

Authors:  John Feehally; Martin Farrall; Anne Boland; Daniel P Gale; Ivo Gut; Simon Heath; Ashish Kumar; John F Peden; Patrick H Maxwell; David L Morris; Sandosh Padmanabhan; Timothy J Vyse; Anna Zawadzka; Andrew J Rees; Mark Lathrop; Peter J Ratcliffe
Journal:  J Am Soc Nephrol       Date:  2010-07-01       Impact factor: 10.121

2.  The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults.

Authors:  Rosanna Coppo; Stéphan Troyanov; Roberta Camilla; Ronald J Hogg; Daniel C Cattran; H Terence Cook; John Feehally; Ian S D Roberts; Alessandro Amore; Charles E Alpers; Jonathan Barratt; Francois Berthoux; Stephen Bonsib; Jan A Bruijn; Vivette D'Agati; Giuseppe D'Amico; Steven N Emancipator; Francesco Emma; Franco Ferrario; Fernando C Fervenza; Sandrine Florquin; Agnes B Fogo; Colin C Geddes; Hermann J Groene; Mark Haas; Andrew M Herzenberg; Prue A Hill; Stephen I Hsu; J Charles Jennette; Kensuke Joh; Bruce A Julian; Tetsuya Kawamura; Fernand M Lai; Lei S Li; Philip K Li; Zhi H Liu; Sergio Mezzano; F Paolo Schena; Yasuhiko Tomino; Patrick D Walker; Haiyan Wang; Jan J Weening; Norishige Yoshikawa; Hong Zhang
Journal:  Kidney Int       Date:  2010-03-03       Impact factor: 10.612

3.  Predicting the risk for dialysis or death in IgA nephropathy.

Authors:  François Berthoux; Hesham Mohey; Blandine Laurent; Christophe Mariat; Aida Afiani; Lise Thibaudin
Journal:  J Am Soc Nephrol       Date:  2011-01-21       Impact factor: 10.121

Review 4.  Current therapy for IgA nephropathy.

Authors:  Jürgen Floege; Frank Eitner
Journal:  J Am Soc Nephrol       Date:  2011-09-08       Impact factor: 10.121

Review 5.  Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors.

Authors:  G D'Amico
Journal:  Am J Kidney Dis       Date:  2000-08       Impact factor: 8.860

6.  Characterization of early IgA nephropathy.

Authors:  F M Lai; C C Szeto; P C Choi; P K Li; A W Chan; N L Tang; S F Lui; A Y Wang; K F To
Journal:  Am J Kidney Dis       Date:  2000-10       Impact factor: 8.860

7.  Genome-wide association study identifies susceptibility loci for IgA nephropathy.

Authors:  Ali G Gharavi; Krzysztof Kiryluk; Murim Choi; Yifu Li; Ping Hou; Jingyuan Xie; Simone Sanna-Cherchi; Clara J Men; Bruce A Julian; Robert J Wyatt; Jan Novak; John C He; Haiyan Wang; Jicheng Lv; Li Zhu; Weiming Wang; Zhaohui Wang; Kasuhito Yasuno; Murat Gunel; Shrikant Mane; Sheila Umlauf; Irina Tikhonova; Isabel Beerman; Silvana Savoldi; Riccardo Magistroni; Gian Marco Ghiggeri; Monica Bodria; Francesca Lugani; Pietro Ravani; Claudio Ponticelli; Landino Allegri; Giuliano Boscutti; Giovanni Frasca; Alessandro Amore; Licia Peruzzi; Rosanna Coppo; Claudia Izzi; Battista Fabio Viola; Elisabetta Prati; Maurizio Salvadori; Renzo Mignani; Loreto Gesualdo; Francesca Bertinetto; Paola Mesiano; Antonio Amoroso; Francesco Scolari; Nan Chen; Hong Zhang; Richard P Lifton
Journal:  Nat Genet       Date:  2011-03-13       Impact factor: 38.330

8.  The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility.

Authors:  Ian S D Roberts; H Terence Cook; Stéphan Troyanov; Charles E Alpers; Alessandro Amore; Jonathan Barratt; Francois Berthoux; Stephen Bonsib; Jan A Bruijn; Daniel C Cattran; Rosanna Coppo; Vivette D'Agati; Giuseppe D'Amico; Steven Emancipator; Francesco Emma; John Feehally; Franco Ferrario; Fernando C Fervenza; Sandrine Florquin; Agnes Fogo; Colin C Geddes; Hermann-Josef Groene; Mark Haas; Andrew M Herzenberg; Prue A Hill; Ronald J Hogg; Stephen I Hsu; J Charles Jennette; Kensuke Joh; Bruce A Julian; Tetsuya Kawamura; Fernand M Lai; Lei-Shi Li; Philip K T Li; Zhi-Hong Liu; Bruce Mackinnon; Sergio Mezzano; F Paolo Schena; Yasuhiko Tomino; Patrick D Walker; Haiyan Wang; Jan J Weening; Nori Yoshikawa; Hong Zhang
Journal:  Kidney Int       Date:  2009-07-01       Impact factor: 10.612

9.  The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification.

Authors:  Daniel C Cattran; Rosanna Coppo; H Terence Cook; John Feehally; Ian S D Roberts; Stéphan Troyanov; Charles E Alpers; Alessandro Amore; Jonathan Barratt; Francois Berthoux; Stephen Bonsib; Jan A Bruijn; Vivette D'Agati; Giuseppe D'Amico; Steven Emancipator; Francesco Emma; Franco Ferrario; Fernando C Fervenza; Sandrine Florquin; Agnes Fogo; Colin C Geddes; Hermann-Josef Groene; Mark Haas; Andrew M Herzenberg; Prue A Hill; Ronald J Hogg; Stephen I Hsu; J Charles Jennette; Kensuke Joh; Bruce A Julian; Tetsuya Kawamura; Fernand M Lai; Chi Bon Leung; Lei-Shi Li; Philip K T Li; Zhi-Hong Liu; Bruce Mackinnon; Sergio Mezzano; F Paolo Schena; Yasuhiko Tomino; Patrick D Walker; Haiyan Wang; Jan J Weening; Nori Yoshikawa; Hong Zhang
Journal:  Kidney Int       Date:  2009-07-01       Impact factor: 10.612

10.  Clinical course and prognostic factors of clinical early IgA nephropathy.

Authors:  P Shen; L He; D Huang
Journal:  Neth J Med       Date:  2008-06       Impact factor: 1.422

View more
  60 in total

1.  Mesangial Deposition Can Strongly Involve Innate-Like IgA Molecules Lacking Affinity Maturation.

Authors:  Batoul Wehbi; Christelle Oblet; François Boyer; Arnaud Huard; Anne Druilhe; François Paraf; Etienne Cogné; Jeanne Moreau; Yolla El Makhour; Bassam Badran; Marjolein Van Egmond; Michel Cogné; Jean-Claude Aldigier
Journal:  J Am Soc Nephrol       Date:  2019-06-21       Impact factor: 10.121

Review 2.  Immunoglobulin A nephropathy: a pathophysiology view.

Authors:  Rafaela Cabral Gonçalves Fabiano; Sérgio Veloso Brant Pinheiro; Ana Cristina Simões E Silva
Journal:  Inflamm Res       Date:  2016-06-28       Impact factor: 4.575

Review 3.  IgA Nephropathy.

Authors:  Jennifer C Rodrigues; Mark Haas; Heather N Reich
Journal:  Clin J Am Soc Nephrol       Date:  2017-02-03       Impact factor: 8.237

4.  Effect of hematuria on the outcome of IgA nephropathy with mild proteinuria.

Authors:  Kayu Tanaka; Takahito Moriyama; Chihiro Iwasaki; Takashi Takei; Kosaku Nitta
Journal:  Clin Exp Nephrol       Date:  2014-12-05       Impact factor: 2.801

5.  IgA nephropathy: is a new approach beyond proteinuria necessary?

Authors:  Eduardo Gutiérrez
Journal:  Pediatr Nephrol       Date:  2019-02-18       Impact factor: 3.714

6.  A case of IgA nephropathy with deep venous thrombosis in the mesentery and lower extremities.

Authors:  Hong Tang; Lei Zhang; Wei Zhao; Rongquan Chen; Min Xie
Journal:  Quant Imaging Med Surg       Date:  2018-12

Review 7.  Pathology of IgA nephropathy.

Authors:  Ian S D Roberts
Journal:  Nat Rev Nephrol       Date:  2014-05-27       Impact factor: 28.314

8.  Mesangial C4d Deposits in Early IgA Nephropathy.

Authors:  Alfons Segarra; Katheryne Romero; Irene Agraz; Natalia Ramos; Alvaro Madrid; Clara Carnicer; Elias Jatem; Ramón Vilalta; Luis Enrique Lara; Elena Ostos; Naiara Valtierra; Juliana Jaramillo; Karla V Arredondo; Gema Ariceta; Cristina Martinez
Journal:  Clin J Am Soc Nephrol       Date:  2017-11-16       Impact factor: 8.237

9.  Update on immunoglobulin A nephropathy, Part I: Pathophysiology.

Authors:  Maurizio Salvadori; Giuseppina Rosso
Journal:  World J Nephrol       Date:  2015-09-06

10.  Association of C4d deposition with clinical outcomes in IgA nephropathy.

Authors:  Mario Espinosa; Rosa Ortega; Marina Sánchez; Alfons Segarra; Maria Teresa Salcedo; Fayna González; Rafael Camacho; Miguel Angel Valdivia; Rocio Cabrera; Katia López; Fernando Pinedo; Eduardo Gutierrez; Alfonso Valera; Miryam Leon; Maria Angeles Cobo; Rosa Rodriguez; Jose Ballarín; Yolanda Arce; Beatriz García; María Dolores Muñoz; Manuel Praga
Journal:  Clin J Am Soc Nephrol       Date:  2014-02-27       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.